AmyPore

AmyPore is dedicated to the research, development and valorization of new processes, products, innovative molecules in the pharmaceutical field and aimed at treating or improving the condition of patients suffering from proteinopathies, in particular neurodegenerative diseases and certain forms of diabetes, or to prevent the appearance of these diseases. The participation, acquisition, exploitation or transfer of all patent processes and intellectual property rights linked to these activities. Its molecule targeting a mechanism common to Alzheimer's and Parkinson's diseases, AmyP53, has successfully passed regulatory preclinical tests and will soon be in phase 1 clinical trial in humans. The challenge is to provide patients with a nasal spray for the prevention and treatment of these diseases.